# US 2025/0367262 A1 · Compositions and methods for intrauterine insemination (iui)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367262 A1
- Document ID: US20250367262A1
- Status: Published application
- Kind: A1
- Application number: 18/874,466
- Filed: 2023-07-10
- Published: 2025-12-04
- Earliest claimed: 2022-07-08
- Assignees: Ferring B.V.
- Applicants: Ferring B.V.
- Inventors: Francois BISSONNETTE; Isaac-Jacques KADOCH
- Web page: https://patentgrep.com/patent/US20250367262A1

## CPC

- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61B 17/43: for artificial insemination
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods, uses and compositions including FSH for use in the treatment of infertility by intrauterine insemination are described.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of treating infertility by intrauterine insemination, comprising administering to a patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the patient has a serum Anti-Mullerian hormone (AMH) level of <15 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.048 μg to 0.052 μg, rFSH per kg bodyweight of the patient per day.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the composition is administered at a dose of 0.05 μg rFSH per kg bodyweight of the patient per day.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the method further comprises, prior to the administering, determining the serum AMH level of the patient, and administering the dose to a patient having a serum AMH level of <15 pmol/L.

### Claim 26 (depends on 23)

The method according to claim 23, wherein the patient is of age <35 years.

### Claim 27 (depends on 23)

The method according to claim 23, wherein the patient is of age 35 to 40 years.

### Claim 28 (depends on 23)

The method according to claim 23, wherein the patient is of age >40 years.

### Claim 29 (depends on 23)

The method according to claim 23, wherein the rFSH includes α2,3- and α2,6-sialylation.

### Claim 30 (depends on 23)

The method according to claim 23, wherein the rFSH includes α2,3- and α2,6-sialylation, wherein 5% to 20% of the total sialylation is α2,6-sialylation and 80% to 95% of the total sialylation is α2,3-sialylation.

### Claim 31 (depends on 23)

The method according to claim 23, wherein the rFSH has been produced or expressed in a human cell line.

### Claim 32 (depends on 23)

The method according to claim 23, wherein the method comprises controlled ovarian stimulation for intrauterine insemination.

### Claim 33 (depends on 23)

The method according to claim 23, wherein the method further comprises a step of triggering ovulation and, optionally, a step of intrauterine insemination.

### Claim 34

A method of treating infertility by intrauterine insemination, comprising administering to a patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the patient has a serum Anti-Mullerian hormone (AMH) level of ≥15 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.025 μg to 0.0475 μg rFSH per kg bodyweight of the patient per day.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the patient has polycystic ovary syndrome (PCOS).

### Claim 36 (depends on 34)

The method according to claim 34, wherein the composition is administered at a dose of 0.025 μg to 0.0475 μg rFSH per kg bodyweight of the patient per day.

### Claim 37 (depends on 34)

The method according to claim 34, wherein the method further comprises, prior to the administering, determining the serum AMH level of the patient, and administering the dose to a patient having a serum AMH level of ≥15 pmol/L.

### Claim 38 (depends on 34)

The method according to claim 34, wherein the rFSH includes α2,3- and α2,6-sialylation.

### Claim 39 (depends on 34)

The method according to claim 34, wherein the rFSH includes α2,3- and α2,6-sialylation, wherein 5% to 20% of the total sialylation is α2,6-sialylation and 80% to 95% of the total sialylation is α2,3-sialylation.

### Claim 40

A method of treating infertility by intrauterine insemination in a patient with PCOS, comprising administering to a PCOS patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the PCOS patient has a serum Anti-Mullerian hormone (AMH) level of ≥23 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.025 μg to 0.0475 μg rFSH per kg bodyweight of the patient per day.

### Claim 41

A method of treating infertility by intrauterine insemination in a patient with PCOS, comprising administering to a PCOS patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH) that includes α2,3- and α2,6 sialylation, wherein the composition is administered at a daily dose of 3 to 7 μg rFSH.

### Claim 42 (depends on 41)

The method of claim 41, wherein the patient has BMI of 30 kg/m2 or more.
